PA-SYNERGIS-SOFTWARE
24.3.2022 13:23:11 CET | Business Wire | Press release
Synergis Software , a global leader in engineering document management and workflow solutions, announced today that Synergis Adept was named as a Leader in the Enterprise Content Management and Product Data Management categories in the G2 Spring 2022 Grid® Reports. G2 is a peer-to-peer business software review website that helps companies choose the best tools for their business. Products in the Leader quadrant are rated highly by verified users of the software product and have significant market presence scores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005238/en/
According to G2’s 2022 Spring Reports, Adept software earned 18 G2 Badges with top placements for “Best Usability”, “Fastest Implementation”, “Ease of Setup”, “Ease of Admin”, and “Highest User Adoption”, and grade the company as “Easiest to do Business With” and “Best Support”—recognition Synergis has received consistently over the past seven quarters.
“These achievements reflect the experience we deliver with our software and the relationships we build with some of the world’s best companies,” says Scott Lamond, vice president of marketing at Synergis Software. “Delivering value in ways that are meaningful to our customers is our top priority, so the G2 results really matter to us. Our customers range from small to very large across varied industries , and they’re all part of the Synergis family. We’re grateful for their trust and inspired to bring them even greater value as we grow together.”
G2 highlights the value of Adept engineering document management software across three categories: Enterprise Content Management, Product Data Management, and Construction Drawing Management. G2 Spring 2022 badges include:
- Leader Enterprise Content Management (ECM)
- Leader Product Data Management (PDM)
- Momentum Leader Enterprise Content Management (ECM)
- Momentum Leader Product Data Management (PDM)
- High Performer Mid-Market Enterprise Content Management (ECM)
- High Performer Mid-Market Product Data Management (PDM)
- High Performer Construction Management
- High Performer Construction Drawing Management
- Best Relationship
- Best Support
- Best Support Small-Business
- Easiest To Do Business With Mid-Market
- Easiest To Do Business With
- Easiest To Do Business With Small-Business
- Fastest Implementation
- Highest User Adoption
- Most Implementable
- Best Usability
The G2 reports are based on direct customer feedback combined with G2’s unique algorithm that calculates customer satisfaction and market presence scores in real-time.
For more details about Adept in the G2 Spring 2022 Reports, visit our website .
Quotes from Verified Users about Synergis Adept
“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites."
Teresa Yang, Product Manager, Document Management, Dow Chemical
“No other software company anywhere works as closely with their customers. The staff is incredibly responsive and consistently goes above and beyond to solve customer issues. For a system your business cannot operate without, this is invaluable.”
Ryan Mongeau, Director of Technology, Space Age Electronics
“Adept has improved our efficiency/processes by 200%. What once took hours in the old systems, I can do in minutes. It’s a very powerful system with unlimited possibilities for adding more useful information for future projects. And the Helpdesk team can tackle and/or resolve any issue I bring to them to improve or streamline our processes.”
Milias H, The Folger Company, Document Control Service Provider
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded.
Adept has been battle tested by engineers for over 30 years with customers such as Dow Chemical, Con Edison, General Mills, Merck, NASA, and Nucor Steel.
About G2 Crowd
G2 is the world’s largest tech marketplace where businesses can discover, review, and manage the technology they need to reach their potential. Today, more than 3M people visit G2 to read and write authentic reviews about thousands of software products and professional services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005238/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom